Twist Bioscience (MIL:1TWST) Piotroski F-Score: 3 (As of Aug. 07, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1TWST Twist Bioscience Corp MIL:1TWST
47 GF Score
Price €97.44
GF Value €46.60
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Twist Bioscience Piotroski F-Score?

Twist Bioscience MIL:1TWST +0.64% 47 Piotroski F-Score is 3 as of Aug. 07, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates MIL:1TWST with a GF Score™ of 47/100 and a GF Value™ of €46.60 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Twist Bioscience ranks worse than 73.91% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Twist Bioscience has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Twist Bioscience's Piotroski F-Score or its related term are showing as below:

MIL:1TWST' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 3

During the past 10 years, the highest Piotroski F-Score of Twist Bioscience was 6. The lowest was 2. And the median was 4.

Twist Bioscience  (MIL:1TWST) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Twist Bioscience Piotroski F-Score Related Terms


Twist Bioscience Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Twist Bioscience's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Twist Bioscience Piotroski F-Score Chart

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 2.00 3.00 5.00

Twist Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 4.00 3.00

MIL:1TWST vs BLLN, SHC, RDNT: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Twist Bioscience's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Twist Bioscience Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's Piotroski F-Score falls into.


MIL:1TWST
47GF Score
Twist Bioscience Corp MIL:1TWST
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -23.122 + -26.053 + -38.078 + -30.424 = €-117.7 Mil.
Cash Flow from Operations was -10.066 + -21.191 + -15.189 + 0.968 = €-45.5 Mil.
Revenue was 84.356 + 88.558 + 95.768 + 102.75 = €371.4 Mil.
Gross Profit was 43.313 + 46.092 + 49.411 + 54.21 = €193.0 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(558.006 + 546.866 + 544.925 + 584.925 + 583.675) / 5 = €563.6794 Mil.
Total Assets at the begining of this year (Jun25) was €558.0 Mil.
Long-Term Debt & Capital Lease Obligation was €73.7 Mil.
Total Current Assets was €278.9 Mil.
Total Current Liabilities was €104.4 Mil.
Net Income was -31.224 + -30.172 + -36.378 + 17.678 = €-80.1 Mil.

Revenue was 76.324 + 84.721 + 85.834 + 83.281 = €330.2 Mil.
Gross Profit was 34.448 + 40.912 + 42.576 + 44.474 = €162.4 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(592.812 + 553.505 + 581.194 + 550.944 + 558.006) / 5 = €567.2922 Mil.
Total Assets at the begining of last year (Jun24) was €592.8 Mil.
Long-Term Debt & Capital Lease Obligation was €54.3 Mil.
Total Current Assets was €294.6 Mil.
Total Current Liabilities was €75.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Twist Bioscience's current Net Income (TTM) was -117.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Twist Bioscience's current Cash Flow from Operations (TTM) was -45.5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=-117.677/558.006
=-0.21088841

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-80.096/592.812
=-0.13511197

Twist Bioscience's return on assets of this year was -0.21088841. Twist Bioscience's return on assets of last year was -0.13511197. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Twist Bioscience's current Net Income (TTM) was -117.7. Twist Bioscience's current Cash Flow from Operations (TTM) was -45.5. ==> -45.5 > -117.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=73.745/563.6794
=0.13082791

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=54.317/567.2922
=0.09574784

Twist Bioscience's gearing of this year was 0.13082791. Twist Bioscience's gearing of last year was 0.09574784. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=278.884/104.381
=2.67178893

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=294.586/75.49
=3.90231819

Twist Bioscience's current ratio of this year was 2.67178893. Twist Bioscience's current ratio of last year was 3.90231819. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Twist Bioscience's number of shares in issue this year was 62.403. Twist Bioscience's number of shares in issue last year was 61.164. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=193.026/371.432
=0.51968059

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=162.41/330.16
=0.49191301

Twist Bioscience's gross margin of this year was 0.51968059. Twist Bioscience's gross margin of last year was 0.49191301. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=371.432/558.006
=0.66564159

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=330.16/592.812
=0.55693879

Twist Bioscience's asset turnover of this year was 0.66564159. Twist Bioscience's asset turnover of last year was 0.55693879. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Twist Bioscience has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Twist Bioscience (MIL:1TWST) has a Piotroski F-Score of 3 as of Aug. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Twist Bioscience and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Twist Bioscience's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Twist Bioscience ranks #153 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 73.9%.
Is Twist Bioscience's Piotroski F-Score too high?
Twist Bioscience's current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Twist Bioscience's value of 3 is 40% below this industry median. Based on the distribution chart, Twist Bioscience ranks #153 out of 207 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Twist Bioscience has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Piotroski F-Score compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #153 out of 207 companies for Piotroski F-Score. This places Twist Bioscience in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Twist Bioscience's value of 3 is 40% below this benchmark. Historically, Twist Bioscience's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Twist Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Twist Bioscience's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Twist Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (MIL:1TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.60, compared to a current price of €97.44 — trading 109.1% above its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 40% below the Medical Diagnostics & Research industry median of 5.00. Twist Bioscience's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Twist Bioscience (MIL:1TWST), the current Piotroski F-Score is 3 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Twist Bioscience (MIL:1TWST) Overvalued in 2026?

Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued. The current stock price of €97.44 is trading 109.1% above its estimated GF Value™ of €46.60. GuruFocus considers Twist Bioscience to be Significantly Overvalued.

Key valuation signals for MIL:1TWST:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: €46.60 vs. price of €97.44 (109.1% above fair value)
  • GF Score™: 47/100 with 5 warning signs
  • Industry Position: 40% below the Medical Diagnostics & Research median (#153 of 207)

No single metric tells the full story. See the MIL:1TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Twist Bioscience Business Description

Other Exchanges TWST:USA0ME:Germany
Address 681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
47GF Score

Get the complete analysis for MIL:1TWST

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€97.44
Price
€46.60
GF Value